SciELO - Scientific Electronic Library Online

 
vol.24 issue4Psychosocial risk factors for illicit drug use in a sample of Mexican high school studentsAgricultural toxic use and temporal distribution of male birth rate in the state of Paraná, Brazil author indexsubject indexarticles search
Home Page  

Revista Panamericana de Salud Pública

Print version ISSN 1020-4989

Abstract

MACHADO, Márcio  and  UNIVERSIDAD NACIONAL DE COLOMBIA PHARMACOECONOMICS GROUP et al. Pharmacoeconomics of antidepressants in moderate-to-severe depressive disorder in Colombia. Rev Panam Salud Publica [online]. 2008, vol.24, n.4, pp. 233-239. ISSN 1020-4989.  http://dx.doi.org/10.1590/S1020-49892008001000002.

OBJECTIVE: To compare three antidepressant drugs from different classes used in treating moderate-to-severe major depressive disorder (MDD) in Colombian adults. METHODS: Based on expert input, a decision-tree model was adapted for Colombia to analyze data over 6 months from the government-payer perspective. The cost-effectiveness of amitriptyline, fluoxetine, and venlafaxine was determined. The clinical outcome was remission of depression (a score <7 on the Hamilton Depression [HAM-D] scale or <12 on the Montgomery-Åsberg Depression Rating Scale [MADRS]) after 8 weeks of treatment. Clinical data were obtained from the literature and costs from standard Colombian price lists. One-way and multivariate sensitivity analyses tested model robustness. RESULTS: Costs per patient (in 2007 US$) for treatment were: venlafaxine, $1 618; fluoxetine, $1 207; and amitriptyline, $1 068. Overall remission rates were 73.1%, 64.1%, and 71.3%, respectively. Amitriptyline dominated fluoxetine (i.e., it had lower costs and higher outcomes). The incremental cost-effectiveness ratio (ICER) of venlafaxine over amitriptyline was US$ 31 595. The acquisition price of venlafaxine was the model's cost driver, comprising 53.4% of the total cost/patient treated, compared with 18.5% and 24.8% for fluoxetine and amitriptyline, respectively. For the others, hospitalization comprised the major cost (72.1% and 65.2%, respectively). Probabilistic (Monte Carlo) sensitivity analysis confirmed the original findings of the pharmacoeconomic model. CONCLUSIONS: Amitriptyline is cost-effective in comparison to fluoxetine and venlafaxine in Colombia. However, the cost of venlafaxine was estimated for the brand-name product, as generics were not currently available. These cost-effectiveness results can be substantially affected by the presence of generics or drug cost regulations.

Keywords : Pharmaceutical economics; antidepressant agents; decision support techniques; Colombia.

        · abstract in Spanish     · text in English     · pdf in English